SEC Form 4 · accession 0000897069-26-001414
Processa Pharmaceuticals, Inc. · PCSA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Young
Officer — Pres. Research & Development · Director
Period of report
Jun 15, 2026
Accepted (ET)
Jun 16, 2026 · 4:24 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001533743
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 15, 2026 | P | 2,067 | $2.22 | A | 19,198 | D | |
| Common Stock | holding | — | — | — | 1,242 | I | By Young-Plaisance Revocable Trust | |
| Common Stock | holding | — | — | — | 432 | I | By Family Entities | |
| Common Stock | holding | — | — | — | 1,009 | I | By CorLyst, LLC |
Table II — derivative securities
No Table II lines on this filing.